Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Mar 4;13(1):1162.
doi: 10.1038/s41467-022-28825-4.

The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers' unvaccinated household members

Jussipekka Salo  1   2   3   4 , Milla Hägg  1   2   3   4 , Mika Kortelainen  2   4   5   6 , Tuija Leino  7 , Tanja Saxell  2   4 , Markku Siikanen  2   4 , Lauri Sääksvuori  8   9   10
Affiliations
Observational Study

The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers' unvaccinated household members

Jussipekka Salo et al. Nat Commun. .

Abstract

Mass vaccination is effective in reducing SARS-CoV-2 infections among vaccinated individuals. However, it remains unclear how effectively COVID-19 vaccines prevent people from spreading the virus to their close contacts. Using nationwide administrative datasets on SARS-CoV-2 infections, vaccination records, demographics, and unique household IDs, we conducted an observational cohort study to estimate the direct and indirect effectiveness of mRNA-based COVID-19 vaccines in reducing infections among vaccinated healthcare workers and their unvaccinated household members. Our estimates for adults imply indirect effectiveness of 39.1% (95% CI: -7.1% to 65.3%) two weeks and 39.0% (95% CI: 18.9% to 54.0%) eight weeks after the second dose. We find that the indirect effect of mRNA-based COVID-19 vaccines within households is smaller for unvaccinated children than for adults and statistically insignificant. Here, we show that mRNA-based COVID-19 vaccines are associated with a reduction in SARS-CoV-2 infections not only among vaccinated individuals but also among unvaccinated adult household members in a real-world setting.

PubMed Disclaimer

Conflict of interest statement

M.K. declares to his employer a grant, but no personal support or financial relationship, from Pfizer during the conduct of the study. The other authors have no competing interest to declare.

Figures

Fig. 1
Fig. 1. Vaccine effectiveness in vaccinated healthcare workers and their unvaccinated partners living in the same household.
This figure plots vaccine effectiveness estimates by week after the first dose of mRNA-based vaccination. The dependent variable is a polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection as recorded in the Finnish National Infectious Diseases Register. a Direct effectiveness estimates (relative risk reduction) for vaccinated individuals compared to the control group, which is constructed by randomly assigning the beginning of a follow-up period for unvaccinated individuals. N = 265,326 healthcare worker observations. b Indirect effectiveness estimates (relative risk reduction) for the unvaccinated partners (including cohabiting partners) of vaccinated individuals who lived in the same household as the vaccinated person as of December 31, 2019. N = 128,952 partner observations. The coefficients in both panels are estimated using a log-binomial regression model and individual-date data collapsed to individual-week data. See section Methods, Estimation samples, for details of the sample restrictions and estimation method. The relative risk reduction is presented as a percentage in data points ±95% confidence intervals. The solid black dots show relative risk reduction by week after receiving the first dose of mRNA-based vaccination. The error bars denote the 95% confidence intervals clustered at the individual level using endpoint transformation of the originally estimated confidence intervals.
Fig. 2
Fig. 2. Vaccine effectiveness in unvaccinated children and adolescents.
This figure plots vaccine effectiveness estimates by week after the first dose of mRNA-based vaccination. The dependent variable is a polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection as recorded in the Finnish National Infectious Diseases Register. a Effectiveness estimates (relative risk reduction) for unvaccinated household members aged from 3 to 18 years who lived in the same household as the vaccinated person as of December 31, 2019. N = 169,148 child and adolescent observations. b Effectiveness estimates (relative risk reduction) separately for unvaccinated children aged from 3 to 12 years and adolescents aged from 13 to 18 years who lived in the same household as the vaccinated person as of December 31, 2019. a and b stack the estimates from follow-up weeks 2 to 5 into a single estimate as there is too few PCR-confirmed SARS-CoV-2 infections to make any inference about the short-term effectiveness of mRNA-based vaccination in this age group. N = 105,186 child (3–12 years) observations, 63,962 adolescent (13–18 years) observations. The estimate for weeks 2–5 represents the average vaccine effectiveness in weeks 2, 3, 4, and 5. The coefficients in both panels are estimated using a log-binomial regression model and individual-date data collapsed to individual-week data. See section Methods, Estimation samples, for details of the sample restrictions and estimation method. The relative risk reduction is presented as a percentage in data points ±95% confidence intervals. The solid black dots show relative risk reduction by week after receiving the first dose of mRNA-based vaccination. The error bars denote the 95% confidence intervals clustered at the individual level using endpoint transformation of the originally estimated confidence intervals.
Fig. 3
Fig. 3. Vaccine effectiveness among fully (double) vaccinated healthcare workers and their unvaccinated partners and children living in the same household after the second vaccine dose.
This figure plots the vaccine effectiveness estimates by week after the second dose of mRNA-based vaccination. The dependent variable is a polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection as recorded in the Finnish National Infectious Diseases Register. a Direct effectiveness estimates (relative risk reduction) for vaccinated individuals compared to an unvaccinated control group, which is constructed by randomly assigning the beginning of a follow-up period for unvaccinated individuals. N = 216,557 healthcare worker observations. b Indirect effectiveness estimates (relative risk reduction) for the unvaccinated partners (including cohabiting partners) of fully vaccinated individuals who lived in the same household as the vaccinated person as of December 31, 2019. N = 110,426 partner observations. c Indirect effectiveness estimates (relative risk reduction) for unvaccinated household members aged from 3 to 18 years who lived in the same household as the vaccinated person as of December 31, 2019. N = 144,935 child and adolescent observations. d Effectiveness estimates (relative risk reduction) separately for unvaccinated children aged from 3 to 12 years and adolescents aged from 13 to 18 years who lived in the same household as the vaccinated person as of December 31, 2019. N = 91,031 child (3–12 years) observations, 53,904 adolescent (13–18 years) observations. c, d Stack the estimates from follow-up weeks 2–5 into a single estimate as there are too few PCR-confirmed SARS-CoV-2 infections to make any inference about the short-term effectiveness of mRNA-based vaccination in this age group. The estimate for weeks 2–5 represents the average vaccine effectiveness in weeks 2, 3, 4, and 5. The coefficients in all panels are estimated using a log-binomial regression model and individual-date data collapsed to individual-week data. See section Methods, Estimation samples, for details of the sample restrictions and estimation method. The relative risk reduction is presented as a percentage in data points ±95% confidence intervals. The solid black dots show relative risk reduction by week after receiving the second dose of mRNA-based vaccination. The error bars denote the 95% confidence intervals clustered at the individual level using endpoint transformation of the originally estimated confidence intervals.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med, 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Dagan N, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 2021;384:1412–1423. doi: 10.1056/NEJMoa2101765. - DOI - PMC - PubMed
    1. Pritchard E, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat. Med. 2021;27:1–9. doi: 10.1038/s41591-021-01410-w. - DOI - PMC - PubMed
    1. Levine-Tiefenbrun M, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat. Med. 2021;27:790–792. doi: 10.1038/s41591-021-01316-7. - DOI - PubMed

Publication types

MeSH terms